Heart failure & cardiomyopathiesRandomised controlled trial
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
- Design and baseline characteristics paper of the MAPLE-HCM phase 3 randomised trial
- ongoing
Rationale, design and baseline characteristics described; no results reported
Study context
- Population
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (newly diagnosed or on standard-of-care (SOC) drugs)
- Comparison
- Aficamten vs metoprolol
Original publication
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. doi:10.1016/j.jchf.2024.11.011
Summarised from the published abstract; every number is checked against it